Company research
TRex Bio, Inc.
CIK 2139097Updated Oct 19, 2026
SecurityTRXB · NASDAQ · equity
TRXB price & chart
Loading TradingView…
NASDAQ:TRXB on TradingView ↗About the company
We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair. Leveraging our Deep Biology drug discovery and design platform, we integrate tissue-level insights into human biology and Treg function to identify and characterize novel targets and approaches for therapeutic intervention. Our tissue-first conviction and unique insights in Treg biology are the foundation of our pipeline of therapeutic candidates aimed at restoring immune balance and promoting tissue repair for more durable disease control.
In the news
No coverage from other publishers is available.
Recent filings
SCHEDULE 13G - filed by PFIZER INC regarding TRex Bio, Inc.
SCHEDULE 13D - filed by ELI LILLY & Co regarding TRex Bio, Inc.
SCHEDULE 13D - filed by SV Biotech Crossover Opportunities Fund LP regarding TRex Bio, Inc.
4 filing
SCHEDULE 13G - filed by Johnson & Johnson Innovation - JJDC, Inc. regarding TRex Bio, Inc.
Show 5 more recent filings
Offerings
Registration 333-299018
- Gross proceeds
- 116666676.0
- Net proceeds
- 108500009.0
- Deal price
- 14.0
- Shares
- 8333334
- Offering price
- $14.00
- Ticker
- TRXB
Underwriters: Number of Shares, Vested
Filing attachments
trexbioinc_ex99-1.htm · SCHEDULE 13D · 2026-10-16
Exhibit 99.1 SCHEDULE A Information regarding members of the investment committee of SV BCO I GP LLP: Name Residence Present Name Citizenship or principal of Employer Business …
Read attachment ↗ck0002139097-ex4_1.htm · S-1/A · 2026-10-05
Exhibit 4.1 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS#. COMMON STOCK [Alt text was not generated.] COMMON STOCKPAR VALUE $.0001 [Alt text was not generated.] PO Box 43004, Providence RI 02940-3004 MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 Shares Certificate Number **000000****************** ***000000***************** ****000000**************** *****000000*************** ******000000************** ZQ00000000 TRex Bio, Inc. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAW…
Read attachment ↗ck0002139097-ex4_2.htm · S-1/A · 2026-10-05
Exhibit 4.2 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of November 7, 2024, by and among TRex Holdings Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and any additional Person that becomes a party to this Agreement in accordance with Section 6.9. RECITALS WHEREAS, the Company and certa…
Read attachment ↗